{
    "clinical_study": {
        "@rank": "100966", 
        "arm_group": {
            "arm_group_label": "GlucoClear System", 
            "description": "NA"
        }, 
        "brief_summary": {
            "textblock": "The primary purpose of this Study is evaluation of the safety and performance of the\n      GlucoClear System (System).\n\n      The primary safety objective will be assessed by:\n\n      \u2022 Evaluation of any serious adverse device effects upon Sensor insertion through Sensor\n      removal and a follow-up assessment one week (7 \u00b1 3 days) after Sensor removal.\n\n      The primary performance objective will be evaluated using the following criteria:\n\n      15/20% Performance: Blood glucose measurements from the System must meet the ISO 15197\n      15/20% accuracy criteria (at least 95% of the matched pairs within \u00b1 15 mg/dL of Comparator\n      values \u2264 75 mg/dL and within \u00b120% of Comparator values > 75 mg/dL)."
        }, 
        "brief_title": "GlucoClearTM System ICU Study", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Accurate Blood Glucose Monitoring in Critical Care Setting", 
        "detailed_description": {
            "textblock": "Design: Non-randomized, non-treatment, prospective, open label Study.\n\n      After providing written informed consent, subjects meeting Inclusion/Exclusion Criteria will\n      be connected to the System for a maximum of 72 hours.\n\n      For the purposes of this clinical Study, the System will not display real-time glucose\n      values, glucose trend graphs, or glucose alarms to either the Study Subjects or the Study\n      Site Personnel. There will be no treatment of any Subject based on the output of the System.\n       Diabetes management decisions throughout this Study (if applicable) will be conducted\n      according to hospital procedures.\n\n        -  1 set of laboratory measurements will be drawn per Subject for baseline.\n\n        -  A maximum of 82 blood samples will be drawn per Subject during the 72 hour monitoring\n           session including.\n\n             -  Up to 75 blood samples drawn for comparative glucose measurement on laboratory\n                analyzers.  Blood samples will be taken from the sampling catheter in the\n                peripheral vein in the contralateral extremity (relative to placement of the\n                System) with no more than 25 samples taken within one day (00:00 to 23:59) for\n                glucose measurement on laboratory analyzers (e.g., Yellow Springs Instrument\n                glucose analyzer (YSI), Radiometer blood analyzer);\n\n             -  Up to three (3) sets of laboratory measurements; and\n\n             -  Up to 4 other blood samples, as needed. One week (7 + 3 days) after Sensor\n                removal, subjects will be contacted for a follow-up assessment and document any\n                subsequent adverse events."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2265 18 years\n\n          -  ICU \u2265 24 hours\n\n          -  Signed consent\n\n        Exclusion Criteria:\n\n          -  Transplant patient\n\n          -  Brain injury/surgery patient\n\n          -  End stage medical conditions or diseases\n\n          -  Restricted venous access\n\n          -  History of HIT\n\n          -  Contraindication for anti-coagulation or bleeding disorder\n\n          -  Positive pregnancy test\n\n          -  In other drug, device, or biologic study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Adult patients with an anticipated ICU stay of at least 24 hours."
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02094859", 
            "org_study_id": "2012-05"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Glucose Monitoring", 
        "lastchanged_date": "March 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria", 
                        "zip": "A-8036"
                    }, 
                    "name": "Medical University Graz"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aalst", 
                        "country": "Belgium", 
                        "zip": "9300"
                    }, 
                    "name": "Onze-Lieve-Vrouwziekenhuis"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Belgium"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "GlucoClearTM System ICU Study", 
        "overall_official": {
            "affiliation": "Onze-Lieve-Vrouwziekenhuis", 
            "last_name": "Luc Foubert, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "15/20% Performance: Blood glucose measurements from the System must meet the ISO 15197 15/20% accuracy criteria (at least 95% of the matched pairs within \u00b1 15 mg/dL of Comparator values \u2264 75 mg/dL and within \u00b120% of Comparator values > 75 mg/dL).", 
            "measure": "15/20% Performance", 
            "safety_issue": "No", 
            "time_frame": "During 72 hours of anticipated Sensor dwell time"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02094859"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "12/12.5% Performance: Propor-tion of matched pairs meeting within \u00b1 12 mg/dL for Compara-tor values \u2264 100 mg/dL and within \u00b1 12.5% for Comparator values > 100 mg/dL.", 
            "measure": "12/12.5% Performance", 
            "safety_issue": "No", 
            "time_frame": "During 72 hours of anticipated Sensor dwell time"
        }, 
        "source": "Edwards Lifesciences", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "MedPass International", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "95 bis boulevard Pereire", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "75017 Paris - France", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Edwards Lifesciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}